Table 1.
Patient Characteristics
| Characteristic | Cohort 1 | Cohort 2 | ||
|---|---|---|---|---|
| Non-PTLDS | PTLDSa | Non-PTLDS | PTLDSb | |
| No. | 10 | 11 | 13 | 13 |
| Mean age ± SD at baseline visit (range), years | 50 ± 11 (26–64) | 48 ± 13 (32–70) | 50 ± 14 (25–73) | 44 ± 16 (20–75) |
| Males, n (%) | 2 (20) | 6 (55) | 8 (62) | 4 (31) |
| Single EM at baseline,c n (%) | 8 (80) | 8 (73) | 8 (62) | 10 (77) |
| Symptomatic at study entry, n (%) | 10 (100) | 11 (100) | 13 (100) | 12 (92) |
| Mean no. of symptoms ± SD at baseline visit (range) | 6.9 ± 1.45 (5–10) | 5.18 ± 1.99 (3–9) | 5.15 ± 2.03 (2–8) | 5.07 ± 3.25 (0–10) |
| Mean no. of symptoms ± SD at 1-year visit (range) | 0.2 ± 0.42 (0–1) | 2.09 ± 1.14 (1–4) | 0.62 ± 1.19 (0–4) | 2.46 ± 2.73 (0–10) |
| Mean treated with doxycycline,d n (%) | 9 (90) | 11 (100) | 13 (100) | 13 (100) |
| Treatment duration ± SD (range),e days | 14.33 ± 2.83 (10–21) | 14.91 ± 3.62 (10–20) | 21 ± 0 (21) | 21 ± 0 (21) |
| Follow treatment, n (%) | 0 (0) | 2 (18) | 1 (8) | 4 (31) |
| Prior Lyme disease,f n (%) | 1 (10) | 1 (9.1) | 0 | 0 |
| Two-tier positive,g n (%) | 7 (70) | 7 (64) | 13 (100) | 7 (54) |
Abbreviations: EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; IgM, immunoglobulin M; PTLDS, post-treatment Lyme disease symptoms/syndrome; EM, erythema migrans; WB, western blot.
aPTLDS (symptoms) patients, classified as such if symptoms developed at or within 6 months following diagnosis and persisted for at least 6 months following the completion of antibiotic therapy [5, 11].
bPTLDS (syndrome) patients, classified as such if they met the PTLDS (symptoms) criteria and reported daily life functional impairment [5, 22].
cAll other patients had multiple EMs.
dIn cohort 1, 3 PTLDS and 1 non-PTLDS patients received an additional 1–4 doses of ceftriaxone; treatment for 1 non-PTLDS patient is unknown.
eTreatment duration for 1 non-PTLDS patient is unknown.
fPrior history of Lyme disease diagnosis and successful treatment not including current episode.
gPositive or equivocal EIA/ELISA and positive IgM and/or IgG WB at baseline and/or post-treatment time point.